MedTrace Logo

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD

NCT03024424 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-05-06

No results posted yet for this study

Summary

The goals of this study are:

To assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic counseling in personal analysis of risk for age-related macular degeneration (AMD), and to assess the impact of presymptomatic genetic testing for choroidal neovascularization (CNV).

Conditions

  • Age-Related Macular Degeneration
  • Choroidal Neovascularization
  • Genetic Counseling

Interventions

BEHAVIORAL

Early disclosure

BEHAVIORAL

Late disclosure

Sponsors & Collaborators

Principal Investigators

  • Paul S. Bernstein, MD, PhD · University of Utah Moran Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-08-10
Completion
2017-08-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03024424 on ClinicalTrials.gov